<DOC>
	<DOCNO>NCT01181089</DOCNO>
	<brief_summary>This prospective , randomize , multicenter , dose escalation study determine subject safety , pharmacokinetic , pharmacodynamic response patient SPMS</brief_summary>
	<brief_title>Dose Escalation Study Evaluate Penetration Pharmacodynamic Effects Baminercept Cerebrospinal Fluid ( CSF ) Safety Subjects With Secondary Progressive Multiple Sclerosis ( SPMS )</brief_title>
	<detailed_description>This study prospective , randomize , placebo-controlled , blind , dose escalation study 3 4 cohort define number patient per cohort receive active drug placebo period 4 month follow safety monitor additional 4 month last dose</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>A diagnosis Secondary Progressive Multiple Sclerosis Aged 18 57 year old , time informed consent History clinically important ( determined investigator ) cardiac , endocrinologic , pulmonary , neurologic , immune , psychiatric , hepatic , renal hematologic insufficiency major disease MS ( Multiple Sclerosis ) Inability opinion Investigator comply study requirement Other protocoldefined criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>57 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>